Akero Therapeutics
AKRO
AKRO was delisted on the 8th of December, 2025.
97 hedge funds and large institutions have $700M invested in Akero Therapeutics in 2021 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 43 increasing their positions, 26 reducing their positions, and 19 closing their positions.
65% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 26
10.95% less ownership
Funds ownership: 90.62% → 79.66% (-11%)
11% less funds holding
Funds holding: 109 → 97 (-12)
23% less capital invested
Capital invested by funds: $913M → $700M (-$213M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
63% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 19
99% less call options, than puts
Call options by funds: $44K | Put options by funds: $4.01M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
YCM
Yiheng Capital Management
San Francisco,
California
|
+$34.6M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$19.2M |
| 3 |
BlackRock
New York
|
+$10.8M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
+$8.18M |
| 5 |
State Street
Boston,
Massachusetts
|
+$8.12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$19.5M |
| 2 |
VP
venBio Partners
San Francisco,
California
|
-$6.84M |
| 3 |
Goldman Sachs
New York
|
-$5.08M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$4.15M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$4M |
AKRO Hedge Fund Activity: Q2 2021 in Review
97 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Akero Therapeutics (AKRO) for Q2 2021, worth a combined $700M — down 23% from $913M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of AKRO and 7 opened new positions — a net loss of 12 holders — while 26 trimmed existing stakes and 43 added.
The largest buyer was Yiheng Capital Management, adding an estimated $34.6M. The largest seller was Vivo Capital, exiting entirely with an estimated $19.5M sold.
- 97 institutional investors held Akero Therapeutics (AKRO) as of Q2 2021, down from 109 in Q1 2021.
- Funds reported $700M of Akero Therapeutics stock for Q2 2021, down 23% quarter-over-quarter.
- 7 funds opened new Akero Therapeutics positions in Q2 2021 and 19 closed out, a net change of -12 holders.
- The largest Akero Therapeutics buyer in Q2 2021 was Yiheng Capital Management, an estimated $34.6M added.
- The largest Akero Therapeutics seller in Q2 2021 was Vivo Capital, an estimated $19.5M sold.
Based on aggregated 13F filings for Q2 2021.